A composition for caring for keratin materials, comprising a fatty acid-ester mixture of a plurality, e.g., at least 3, 4, or 5, of medium chain fatty acids and a plurality, e.g., at least 3, 4, or 5, of monoesters; and a cosmetically or dermatologically acceptable auxiliary agent to assist the delivery of the fatty acid-ester mixture to the keratin materials.

A composition for caring for keratin materials, comprising a fatty acid-ester mixture of a plurality, e.g., at least 3, 4, or 5, of medium chain fatty acids and a plurality, e.g., at least 3, 4, or 5, of monoesters; and a cosmetically or dermatologically acceptable auxiliary agent to assist the delivery of the fatty acid-ester mixture to the keratin materials.

The present invention features methods and compositions for preventing, inhibiting, or reducing the sensation of itch (pruritus) by modulating the gene expression of TMEM184B. Modulating the gene expression of TMEM184B may comprise increasing Tmem184B protein expression, increasing Tmem184B protein activity or both. Furthermore, the methods and compositions described herein may activate the Tmem184B protein or activate a pathway leading to Tmem184B activation. Additionally, the methods and compositions for modulating the gene expression of TMEM184B may be used to help prevent or treat certain diseases or conditions such as dermatitis.

The present invention features methods and compositions for preventing, inhibiting, or reducing the sensation of itch (pruritus) by modulating the gene expression of TMEM184B. Modulating the gene expression of TMEM184B may comprise increasing Tmem184B protein expression, increasing Tmem184B protein activity or both. Furthermore, the methods and compositions described herein may activate the Tmem184B protein or activate a pathway leading to Tmem184B activation. Additionally, the methods and compositions for modulating the gene expression of TMEM184B may be used to help prevent or treat certain diseases or conditions such as dermatitis.

The present disclosure provides compositions and methods for promoting stem cell and/or progenitor cell proliferation and/or differentiation. The provided compositions may be useful in treating a disease or condition that is related to mucosal barrier function, e.g., wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or condition related to the aging of skin), treating a lung disorders (e.g., asthma), a condition related to improving mucosal barrier function, and/or treating injury to GI mucosa in a subject in need thereof. The present disclosure also provides methods for promoting the proliferation and/or differentiation of stem cells and/or the progenitor cells in a subject in need of such treatment by administering a composition. The ability to stimulate the proliferation and/or differentiation of stem cells and/or the progenitor cells in vivo, ex vivo and/or in vitro provides tremendous benefit. The present disclosure can be used to increase stem cell populations in in vivo, ex vivo and/or in vitro. Stem cell transplantation provides treatments and/or cures of many disease states, degeneration and/or injury.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

The present invention relates to a collar for non-human animals, preferably for companion animals, comprising a polymeric matrix and a lipid extract comprising sphingomyelins. It also refers to the collar for use as a medicine, particularly for use as an adjuvant and for use in the treatment or prevention of atopic dermatitis or allergic dermatitis, as well as in restoring the integrity of the skin during or after an atopic dermatitis or an allergic dermatitis, increasing the hydration and flexibility of the skin, facilitating skin regeneration or reducing itching of the skin.

The present invention relates to a collar for non-human animals, preferably for companion animals, comprising a polymeric matrix and a lipid extract comprising sphingomyelins. It also refers to the collar for use as a medicine, particularly for use as an adjuvant and for use in the treatment or prevention of atopic dermatitis or allergic dermatitis, as well as in restoring the integrity of the skin during or after an atopic dermatitis or an allergic dermatitis, increasing the hydration and flexibility of the skin, facilitating skin regeneration or reducing itching of the skin.

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.